- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01295892
Chronic Effects of Estrogen in Microcirculation
Chronic Effects of Estrogen in Microcirculation and Insulin Resistance in Postmenopausal Obese Women
Study Overview
Detailed Description
Estrogens exert pleiotropic actions on the cardiovascular system through binding to estrogen receptors. Traditionally, estrogen receptors have been recognized as transcription factors regulating the expression of target genes, however, numerous studies have revealed rapid actions of estrogen in different systems, so-called 'extranuclear actions'. At this level, estrogen triggers rapid vasodilatation, exerts anti-inflammatory effects, regulates vascular cell growth and migration, and confers protection to cardiomyocytes. Our aims are to investigate estrogen´s chronic effects on microcirculation.
The study will assess the potential benefits of estrogens on: chronic low-grade inflammation, metabolic profile, microcirculation and blood rheology. Postmenopausal obese women will be randomly submitted to estrogen (transdermal 17-β-estradiol 1mg/day) or placebo therapy during three months in a double-blind fashion. At baseline and after intervention, nailfold videocapillaroscopy, laser-Doppler flowmetry and venous occlusion plethysmography, inflammatory biomarkers, hormonal status, metabolic profile, plasma viscosity and anthropometrical measures will be assessed in all subjects.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Rio de Janeiro, Brazil
- Laboratorio de Pesquisas Clinicas e Experimentais em Biologia Vascular
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of natural menopause defined by the absence of menses for at least 12 months and a serum concentration of FSH > 35 IU/L
- BMI between 27 to 34.9 kg/m²
- Non-smokers
- Not on use of any hormones or supplements for a minimum of 6 months prior to the study
- No absolute contraindications to the use of physiological replacement doses of estrogen
Exclusion Criteria:
- Renal disease, coronary or peripheral vascular diseases, haematologic or hepatic diseases
- Diabetes mellitus, glucose intolerance or altered fasting glucose
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
placebo (transdermal gel)
|
transdermal 17-β-estradiol 1mg/day during three months
|
Experimental: Estrogen
1mg of 17B-estradiol/day (transdermal gel)
|
transdermal 17-β-estradiol 1mg/day during three months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
functional capillary density by videocapillaroscopy(number of perfused capillaries on the studied skin area)
Time Frame: 03 months
|
03 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
blood viscosity(the values are expressed in centipoises)
Time Frame: 03 months
|
evaluate the change in blood viscosity after 3 months of treatment
|
03 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Diogo Panazzolo, Rio de Janeiro State University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- pkvw6k
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postmenopausal Symptoms
-
Fundació EurecatCompletedMenopause | Postmenopausal Symptoms | Postmenopausal DisorderSpain
-
Merck Sharp & Dohme LLCCompletedPostmenopausal Symptoms
-
University Hospital Inselspital, BerneRecruitingPostmenopausal | Postmenopausal FlushingSwitzerland
-
Milton S. Hershey Medical CenterNot yet recruitingCardiovascular Diseases | Postmenopausal Symptoms
-
F&C Licorice LtdUnknownVaginal Dryness | Postmenopausal SymptomsIsrael
-
Hend HamdyNot yet recruiting
-
University of Erlangen-Nürnberg Medical SchoolElsbeth-Bonhoff-Stiftung, BerlinTerminatedPostmenopausalGermany
-
Warner ChilcottSanofiCompletedPostmenopausalUnited States, Poland, Canada, Croatia, Netherlands
-
Federal University of São PauloUnknownPostmenopausal SymptomsBrazil
-
Mayo ClinicCompletedPostmenopausalUnited States
Clinical Trials on Estrogen
-
University of Southern CaliforniaAstraZenecaTerminatedBreast CarcinomaUnited States
-
Icahn School of Medicine at Mount SinaiAstraZenecaTerminated
-
AstraZenecaCompletedBreast Cancer | MetastasisUnited States, Australia, Brazil, France, Italy, Mexico, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Poland, Japan, Argentina, Austria, Canada, Hungary, Israel, Netherlands, New Zealand, Portugal, Taiwan, Germany, Finlan... and more
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedEndometrial CancerUnited States
-
Fundació Sant Joan de DéuCompleted
-
Eli Lilly and CompanyCompleted
-
Iris SommerAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Ziekenhuis... and other collaboratorsCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Psychosis NOSNetherlands
-
Eunice Kennedy Shriver National Institute of Child...CompletedEndometriosis | Pelvic PainUnited States
-
University of Wisconsin, MadisonNational Institute on Aging (NIA)CompletedAlzheimer DiseaseUnited States
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; AstraZeneca; Brigham and Women's HospitalCompletedBreast Cancer | Hodgkin's DiseaseUnited States